VAD protocol for treatment of advanced refractory multiple myeloma

W. Scheithauer, A. Cortelezzi, R. Kutzmits, L. Baldini, H. Ludwig

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Twenty-three patients with advanced refractory multiple myeloma were treated with a combination chemotherapeutic regimen consisting of four-day continuous infusion of vincristine and doxorubicin plus intermittent high-dose dexamethasone (VAD). All patients included in the study were heavily pretreated with cytostatics and radiotherapeutic measures, and generally presented in poor general condition. In 3 of the 16 evaluable patients (18%) a response, and in 7 patients (44%) an improvement as defined by a reduction in tumor mass by more than 50% was achieved. Six patients had progressive disease. Evaluation of survival for responders (15 mos) versus non-responders (2 mos) by the landmark method seems to confirm the relative therapeutic efficacy of the VAD protocol in refractory multiple myeloma. The somewhat inferior response rate as well as the occurrence of considerable toxicity in several cases (when compared to the recent M. D. Anderson trial) may be related to differences in clinical features and pretreatment status of the two studies' population.

Original languageEnglish
Pages (from-to)145-152
Number of pages8
JournalBlut
Volume55
Issue number3
DOIs
Publication statusPublished - Sep 1987

Fingerprint

Multiple Myeloma
Therapeutics
Cytostatic Agents
Vincristine
Doxorubicin
Dexamethasone
VAD protocol
Survival
Population
Neoplasms

Keywords

  • Chemotherapy
  • Myeloma

ASJC Scopus subject areas

  • Hematology

Cite this

VAD protocol for treatment of advanced refractory multiple myeloma. / Scheithauer, W.; Cortelezzi, A.; Kutzmits, R.; Baldini, L.; Ludwig, H.

In: Blut, Vol. 55, No. 3, 09.1987, p. 145-152.

Research output: Contribution to journalArticle

Scheithauer, W. ; Cortelezzi, A. ; Kutzmits, R. ; Baldini, L. ; Ludwig, H. / VAD protocol for treatment of advanced refractory multiple myeloma. In: Blut. 1987 ; Vol. 55, No. 3. pp. 145-152.
@article{ba15acc3c553407b8217c03332e0cce8,
title = "VAD protocol for treatment of advanced refractory multiple myeloma",
abstract = "Twenty-three patients with advanced refractory multiple myeloma were treated with a combination chemotherapeutic regimen consisting of four-day continuous infusion of vincristine and doxorubicin plus intermittent high-dose dexamethasone (VAD). All patients included in the study were heavily pretreated with cytostatics and radiotherapeutic measures, and generally presented in poor general condition. In 3 of the 16 evaluable patients (18{\%}) a response, and in 7 patients (44{\%}) an improvement as defined by a reduction in tumor mass by more than 50{\%} was achieved. Six patients had progressive disease. Evaluation of survival for responders (15 mos) versus non-responders (2 mos) by the landmark method seems to confirm the relative therapeutic efficacy of the VAD protocol in refractory multiple myeloma. The somewhat inferior response rate as well as the occurrence of considerable toxicity in several cases (when compared to the recent M. D. Anderson trial) may be related to differences in clinical features and pretreatment status of the two studies' population.",
keywords = "Chemotherapy, Myeloma",
author = "W. Scheithauer and A. Cortelezzi and R. Kutzmits and L. Baldini and H. Ludwig",
year = "1987",
month = "9",
doi = "10.1007/BF00320568",
language = "English",
volume = "55",
pages = "145--152",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - VAD protocol for treatment of advanced refractory multiple myeloma

AU - Scheithauer, W.

AU - Cortelezzi, A.

AU - Kutzmits, R.

AU - Baldini, L.

AU - Ludwig, H.

PY - 1987/9

Y1 - 1987/9

N2 - Twenty-three patients with advanced refractory multiple myeloma were treated with a combination chemotherapeutic regimen consisting of four-day continuous infusion of vincristine and doxorubicin plus intermittent high-dose dexamethasone (VAD). All patients included in the study were heavily pretreated with cytostatics and radiotherapeutic measures, and generally presented in poor general condition. In 3 of the 16 evaluable patients (18%) a response, and in 7 patients (44%) an improvement as defined by a reduction in tumor mass by more than 50% was achieved. Six patients had progressive disease. Evaluation of survival for responders (15 mos) versus non-responders (2 mos) by the landmark method seems to confirm the relative therapeutic efficacy of the VAD protocol in refractory multiple myeloma. The somewhat inferior response rate as well as the occurrence of considerable toxicity in several cases (when compared to the recent M. D. Anderson trial) may be related to differences in clinical features and pretreatment status of the two studies' population.

AB - Twenty-three patients with advanced refractory multiple myeloma were treated with a combination chemotherapeutic regimen consisting of four-day continuous infusion of vincristine and doxorubicin plus intermittent high-dose dexamethasone (VAD). All patients included in the study were heavily pretreated with cytostatics and radiotherapeutic measures, and generally presented in poor general condition. In 3 of the 16 evaluable patients (18%) a response, and in 7 patients (44%) an improvement as defined by a reduction in tumor mass by more than 50% was achieved. Six patients had progressive disease. Evaluation of survival for responders (15 mos) versus non-responders (2 mos) by the landmark method seems to confirm the relative therapeutic efficacy of the VAD protocol in refractory multiple myeloma. The somewhat inferior response rate as well as the occurrence of considerable toxicity in several cases (when compared to the recent M. D. Anderson trial) may be related to differences in clinical features and pretreatment status of the two studies' population.

KW - Chemotherapy

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=0023233144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023233144&partnerID=8YFLogxK

U2 - 10.1007/BF00320568

DO - 10.1007/BF00320568

M3 - Article

VL - 55

SP - 145

EP - 152

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -